Jade Biosciences (NASDAQ:JBIO) Stock Price Down 4.6% - What's Next?

Key Points

• Jade Biosciences shares fell 4.6% to about $20.42 in mid-day trading, with volume down 79% from the average session. The company has a $1.27 billion market capitalization and trades below its average analyst target of $51.75.
• Analyst sentiment remains broadly positive, with two Strong Buy and six Buy ratings versus one Hold and one Sell. Recent targets include $47 to $55, although Weiss Ratings slightly downgraded its existing Sell rating.
• The clinical-stage biotechnology company missed quarterly expectations, reporting an adjusted loss of $0.76 per share versus the consensus loss estimate of $0.66. Analysts expect a full-year loss of approximately $2.84 per share as Jade advances small-molecule treatments for inflammatory skin diseases and chronic itch.

Shares of Jade Biosciences, Inc. (NASDAQ:JBIO - Get Free Report) traded down 4.6% during mid-day trading on Thursday . The company traded as low as $19.92 and last traded at $20.4210. Approximately 151,162 shares changed hands during mid-day trading, a decline of 79% from the average session volume of 710,283 shares. The stock had previously closed at $21.40.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. HC Wainwright boosted their price target on shares of Jade Biosciences from $45.00 to $55.00 and gave the company a "buy" rating in a report on Monday, June 1st. Wedbush lifted their price target on shares of Jade Biosciences from $45.00 to $47.00 and gave the company an "outperform" rating in a research note on Monday, August 10th. Weiss Ratings cut Jade Biosciences from a "sell (d)" rating to a "sell (d-)" rating in a research note on Tuesday, June 16th. Piper Sandler set a $55.00 target price on shares of Jade Biosciences in a research note on Tuesday, June 2nd. Finally, Guggenheim reaffirmed a "buy" rating and set a $47.00 price objective on shares of Jade Biosciences in a research report on Tuesday, June 2nd. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $51.75.

Jade Biosciences Trading Down 6.4%

The stock has a market capitalization of $1.27 billion, a P/E ratio of -10.42 and a beta of 1.45. The business has a 50-day moving average price of $21.44 and a two-hundred day moving average price of $19.35.

Jade Biosciences (NASDAQ:JBIO - Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.76) EPS for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.10). On average, sell-side analysts forecast that Jade Biosciences, Inc. will post -2.84 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Jade Biosciences

Hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. acquired a new stake in Jade Biosciences during the 2nd quarter worth approximately $154,000. Legal & General Group Plc bought a new stake in shares of Jade Biosciences in the 2nd quarter valued at about $29,000. Rhumbline Advisers acquired a new stake in Jade Biosciences during the 2nd quarter valued at approximately $445,000. Russell Investments Group Ltd. acquired a new position in Jade Biosciences in the second quarter valued at $31,000. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Jade Biosciences during the 2nd quarter worth approximately $114,000.

About Jade Biosciences

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source